HK1244001B - 用於治疗hiv的喹唑啉衍生物 - Google Patents

用於治疗hiv的喹唑啉衍生物 Download PDF

Info

Publication number: HK1244001B
Authority: HK; Hong Kong
Prior art keywords: compound; alkyl; heteroalkyl; mmol; hiv
Prior art date: 2014-12-24

Application number

HK18103444.6A

Other languages

German (de)

English (en)

French (fr)

Other versions

HK1244001A1 (zh

Inventor

Jansa Petr

Simon Petr

Lansdon Eric

Eric HU Yunfeng

Baszczynski Ondrej

Dejmek Milan

L. Mackman Richard

Original Assignee

Gilead Sciences, Inc.

Institute Of Organic Chemistry And Biochemistry As Cr, V.V.I.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2014-12-24

Filing date

2015-12-23

Publication date

2020-01-10

2015-12-23 Application filed by Gilead Sciences, Inc., Institute Of Organic Chemistry And Biochemistry As Cr, V.V.I. filed Critical Gilead Sciences, Inc.

2018-07-27 Publication of HK1244001A1 publication Critical patent/HK1244001A1/zh

2020-01-10 Publication of HK1244001B publication Critical patent/HK1244001B/zh

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/78—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 2
- C07D239/84—Nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/95—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in positions 2 and 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Virology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Molecular Biology (AREA)
AIDS & HIV (AREA)
Tropical Medicine & Parasitology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

HK18103444.6A 2014-12-24 2015-12-23 用於治疗hiv的喹唑啉衍生物 HK1244001B (zh)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201462096748P	2014-12-24	2014-12-24
US62/096,748		2014-12-24
PCT/US2015/000460 WO2016105564A1 (en)	2014-12-24	2015-12-23	Quinazoline derivatives used to treat hiv

Publications (2)

Publication Number	Publication Date
HK1244001A1 HK1244001A1 (zh)	2018-07-27
HK1244001B true HK1244001B (zh)	2020-01-10

Family

ID=55305044

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HK18103444.6A HK1244001B (zh)	2014-12-24	2015-12-23	用於治疗hiv的喹唑啉衍生物

Country Status (41)

Country	Link
US (5)	US9730936B2 (zh)
EP (4)	EP3521282B1 (zh)
JP (2)	JP6367489B2 (zh)
KR (2)	KR102049476B1 (zh)
CN (2)	CN111574464A (zh)
AR (1)	AR103252A1 (zh)
AU (1)	AU2015371198B2 (zh)
BR (1)	BR102015032361B1 (zh)
CA (1)	CA2972021C (zh)
CL (1)	CL2017001675A1 (zh)
CO (1)	CO2017006214A2 (zh)
CR (1)	CR20170281A (zh)
CU (1)	CU20170089A7 (zh)
CY (1)	CY1124726T1 (zh)
DK (1)	DK3521282T3 (zh)
DO (1)	DOP2017000151A (zh)
EA (2)	EA202091115A1 (zh)
EC (1)	ECSP17039611A (zh)
ES (3)	ES2900810T3 (zh)
HK (1)	HK1244001B (zh)
HR (1)	HRP20211543T1 (zh)
HU (1)	HUE058296T2 (zh)
IL (2)	IL253059B (zh)
LT (1)	LT3521282T (zh)
MA (1)	MA48448A (zh)
MD (1)	MD4650B1 (zh)
MX (2)	MX367574B (zh)
MY (1)	MY189761A (zh)
NZ (1)	NZ733174A (zh)
PE (1)	PE20171306A1 (zh)
PH (1)	PH12017501191B1 (zh)
PL (3)	PL3237398T3 (zh)
PT (2)	PT3521282T (zh)
SA (1)	SA517381826B1 (zh)
SG (2)	SG10202101143VA (zh)
SI (2)	SI3521282T1 (zh)
SV (1)	SV2017005471A (zh)
TR (1)	TR201903672T4 (zh)
TW (3)	TW202237569A (zh)
UA (1)	UA117796C2 (zh)
WO (1)	WO2016105564A1 (zh)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2553449T3 (es)	2011-07-06	2015-12-09	Gilead Sciences, Inc.	Compuestos para el tratamiento de VIH
MX2017008520A (es)	2014-12-24	2018-03-01	Gilead Sciences Inc	Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).
AU2015371257B2 (en)	2014-12-24	2018-09-06	Gilead Sciences, Inc.	Isoquinoline compounds for the treatment of HIV
TW202237569A (zh) *	2014-12-24	2022-10-01	美商基利科學股份有限公司	喹唑啉化合物
EP3939985B1 (en)	2014-12-26	2024-05-08	Emory University	Pharmaceutical compositions comprising n4-hydroxycytidine derivatives for the treatment or prevention of influenza or coronavirus infections
TWI808055B (zh)	2016-05-11	2023-07-11	美商滬亞生物國際有限公司	Hdac 抑制劑與 pd-1 抑制劑之組合治療
TWI794171B (zh)	2016-05-11	2023-03-01	美商滬亞生物國際有限公司	Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
PE20211427A1 (es)	2016-08-19	2021-08-03	Gilead Sciences Inc	Compuestos terapeuticos utiles para el tratamiento profilatico o terapeutico de una infeccion por el virus del vih
AR112413A1 (es)	2017-08-17	2019-10-23	Gilead Sciences Inc	Formas sólidas de un inhibidor de la cápside del vih
AR112412A1 (es)	2017-08-17	2019-10-23	Gilead Sciences Inc	Formas de sal de colina de un inhibidor de la cápside del vih
ES2995458T3 (en)	2017-12-07	2025-02-10	Univ Emory	N4-hydroxycytidine derivative and anti-viral uses related thereto
EP3752495B1 (en)	2018-02-15	2023-07-19	Gilead Sciences, Inc.	Pyridine derivatives and their use for treating hiv infection
TWI823164B (zh)	2018-02-16	2023-11-21	美商基利科學股份有限公司	用於製備有療效化合物之方法及中間物
WO2019204768A1 (en) *	2018-04-20	2019-10-24	The Regents Of The University Of California	Beta-adrenergic receptor allosteric modulators
CA3103522C (en)	2018-07-16	2023-11-21	Gilead Sciences, Inc.	Capsid inhibitors for the treatment of hiv
CA3124569A1 (en)	2018-12-28	2020-07-02	Spv Therapeutics Inc.	Cyclin-dependent kinase inhibitors
CN119462659A (zh)	2019-03-22	2025-02-18	吉利德科学公司	桥连三环氨基甲酰基吡啶酮化合物及其药学用途
TW202104210A (zh)	2019-04-17	2021-02-01	美商基利科學股份有限公司	Hiv蛋白酶抑制劑
US20200347036A1 (en)	2019-04-17	2020-11-05	Gilead Sciences, Inc.	Solid forms of an hiv protease inhibitor
KR20220106165A (ko)	2019-11-26	2022-07-28	길리애드 사이언시즈, 인코포레이티드	Hiv의 예방을 위한 캡시드 억제제
EP4121437A1 (en)	2020-03-20	2023-01-25	Gilead Sciences, Inc.	Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
BR112022021005A2 (pt)	2020-04-24	2022-12-06	Sumitomo Pharma Co Ltd	Derivado de 2-heteroarilaminoquinazolinona
KR20230027275A (ko)	2020-06-25	2023-02-27	길리애드 사이언시즈, 인코포레이티드	Hiv 치료용 캡시드 저해제
KR20230107288A (ko)	2020-11-11	2023-07-14	길리애드 사이언시즈, 인코포레이티드	gp120 CD4 결합 부위-지향 항체를 이용한 요법에 감수성인 HIV 환자를 식별하는 방법
JP7736929B2 (ja)	2021-12-03	2025-09-09	ギリアードサイエンシーズ，インコーポレイテッド	Ｈｉｖウイルス感染症のための治療化合物
TW202342448A (zh)	2021-12-03	2023-11-01	美商基利科學股份有限公司	用於ｈｉｖ病毒感染之治療性化合物
FI4445900T3 (fi)	2021-12-03	2025-08-05	Gilead Sciences Inc	Terapeuttisia yhdisteitä hiv-virusinfektiota varten
TWI856796B (zh)	2022-04-06	2024-09-21	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2024006982A1 (en)	2022-07-01	2024-01-04	Gilead Sciences, Inc.	Therapeutic compounds useful for the prophylactic or therapeutic treatment of an hiv virus infection
EP4577242A1 (en)	2022-08-26	2025-07-02	Gilead Sciences, Inc.	Dosing and scheduling regimen for broadly neutralizing antibodies
US20240226130A1 (en)	2022-10-04	2024-07-11	Gilead Sciences, Inc.	4'-thionucleoside analogues and their pharmaceutical use
AU2024259111A1 (en)	2023-04-19	2025-10-16	Gilead Sciences, Inc.	Dosing regimen of capsid inhibitor
US20250011352A1 (en)	2023-05-31	2025-01-09	Gilead Sciences, Inc.	Solid forms
US20250042926A1 (en)	2023-05-31	2025-02-06	Gilead Sciences, Inc.	Therapeutic compounds for hiv
WO2025029247A1 (en)	2023-07-28	2025-02-06	Gilead Sciences, Inc.	Weekly regimen of lenacapavir for the treatment and prevention of hiv
WO2025042394A1 (en)	2023-08-23	2025-02-27	Gilead Sciences, Inc.	Dosing regimen of hiv capsid inhibitor
WO2025080850A1 (en)	2023-10-11	2025-04-17	Gilead Sciences, Inc.	Bridged tricyclic carbamoylpyridone compounds and uses thereof
WO2025080863A1 (en)	2023-10-11	2025-04-17	Gilead Sciences, Inc.	Bridged tricyclic carbamoylpyridone compounds and uses thereof
TW202515549A (zh)	2023-10-11	2025-04-16	美商基利科學股份有限公司	橋聯三環胺甲醯基吡啶酮化合物及其用途
WO2025137245A1 (en)	2023-12-22	2025-06-26	Gilead Sciences, Inc.	Solid forms of hiv integrase inhibitors
US20250296932A1 (en)	2024-03-01	2025-09-25	Gilead Sciences, Inc.	Pharmaceutical compositions comprising hiv integrase inhibitors
WO2025184609A1 (en)	2024-03-01	2025-09-04	Gilead Sciences, Inc.	Antiviral compounds
WO2025184452A1 (en)	2024-03-01	2025-09-04	Gilead Sciences, Inc.	Solid forms of hiv integrase inhibitors
US20260007683A1 (en)	2024-06-14	2026-01-08	Gilead Sciences, Inc.	Pharmaceutical compositions comprising hiv integrase inhibitors

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ197420A (en)	1980-07-01	1984-04-27	Ici Australia Ltd	-(quinazolin-(2-or 4-)(oxy,ylthio or amino)phen(oxy or ylthio)alkanoic acid derivatives
JPH11209350A (ja)	1998-01-26	1999-08-03	Eisai Co Ltd	含窒素複素環誘導体およびその医薬
AU7031500A (en) *	1999-09-23	2001-04-24	Astrazeneca Ab	Therapeutic quinazoline compounds
CA2386955A1 (en)	1999-11-22	2001-05-31	Warner-Lambert Company	Quinazolines and their use for inhibiting cyclin-dependent kinase enzymes
GB0002032D0 (en)	2000-01-28	2000-03-22	Zeneca Ltd	Chemical compounds
JP2004505110A (ja)	2000-08-02	2004-02-19	セルテック　アール　アンド　ディ　リミテッド	３位置換イソキノリン−１−イル誘導体
CN1474815A (zh)	2000-09-20	2004-02-11	Ĭ��ר��ɷ��޹�˾	4-氨基-喹唑啉
WO2004030672A1 (en)	2002-10-02	2004-04-15	Merck Patent Gmbh	Use of 4 amino-quinazolines as anti cancer agents
PL1628685T3 (pl)	2003-04-25	2011-05-31	Gilead Sciences Inc	Przeciwwirusowe analogi fosfonianowe
WO2004108711A1 (en)	2003-06-05	2004-12-16	Astrazeneca Ab	Pyrazinil quinazoline derivatives for use in the treatment of tumours
JP2007008816A (ja)	2003-10-15	2007-01-18	Ube Ind Ltd	新規イソキノリン誘導体
US8318701B2 (en)	2004-07-27	2012-11-27	Gilead Sciences, Inc.	Phosphonate analogs of HIV inhibitor compounds
US20070054916A1 (en)	2004-10-01	2007-03-08	Amgen Inc.	Aryl nitrogen-containing bicyclic compounds and methods of use
MX2007005159A (es)	2004-10-29	2007-06-26	Tibotec Pharm Ltd	Derivados de pirimidina biciclicos inhibidores del vih.
WO2006071095A1 (en)	2004-12-31	2006-07-06	Sk Chemicals Co., Ltd.	Quinazoline derivatives for the treatment and prevention of diabetes and obesity
US7816352B2 (en)	2005-03-10	2010-10-19	The Regents Of The University Of California	Apoptosis inhibitors
WO2006118256A1 (ja)	2005-04-28	2006-11-09	Kyowa Hakko Kogyo Co., Ltd.	2-アミノキナゾリン誘導体
ATE441641T1 (de)	2005-06-28	2009-09-15	Sanofi Aventis	Isochinolinderivate als inhibitoren von rho- kinase
EP2385047B1 (en)	2005-07-26	2013-05-29	Sanofi	Piperidinyl-substituted isoquinolone derivatives
US7989461B2 (en)	2005-12-23	2011-08-02	Amgen Inc.	Substituted quinazolinamine compounds for the treatment of cancer
EP2044028B1 (en)	2006-01-27	2012-05-16	Fibrogen, Inc.	Cyanoisoquinoline compounds that stabilize hypoxia inducible factor (hif)
AR060358A1 (es)	2006-04-06	2008-06-11	Novartis Vaccines & Diagnostic	Quinazolinas para la inhibicion de pdk 1
WO2007125405A2 (en)	2006-05-01	2007-11-08	Pfizer Products Inc.	Substituted 2-amino-fused heterocyclic compounds
ATE469144T1 (de)	2006-07-20	2010-06-15	Amgen Inc	Substituierte pyridonverbindungen und anwendungsverfahren
US8027888B2 (en)	2006-08-31	2011-09-27	Experian Interactive Innovation Center, Llc	Online credit card prescreen systems and methods
WO2008050808A1 (fr)	2006-10-24	2008-05-02	Kyowa Hakko Kirin Co., Ltd.	Dérivé de 2-aminoquinazoline
WO2008077553A1 (en)	2006-12-27	2008-07-03	Sanofi-Aventis	Cycloalkylamine substituted isoquinolone and isoquinolinone derivatives
CN101595094B (zh)	2006-12-27	2013-02-20	塞诺菲-安万特股份有限公司	环烷基胺取代的异喹诺酮衍生物
RU2455302C2 (ru)	2006-12-27	2012-07-10	Санофи-Авентис	ЗАМЕЩЕННЫЕ ИЗОХИНОЛИНОВЫЕ И ИЗОХИНОЛИНОНОВЫЕ ПРОИЗВОДНЫЕ В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
US20090004185A1 (en)	2007-01-11	2009-01-01	Wyeth	Amino-substituted quinazoline derivatives as inhibitors of beta-catenin/tcf-4 pathway and cancer treatment agents
MX2009010696A (es)	2007-04-06	2009-10-20	Novartis Ag	Derivados de 2,6-naftiridina como moduladores de cinasa de proteina.
WO2008157500A1 (en)	2007-06-17	2008-12-24	Kalypsys, Inc.	Aminoquinazoline cannabinoid receptor modulators for treatment of disease
BRPI0820307A2 (pt)	2007-11-16	2019-09-24	Boehringer Ingelheim Int	inibidores de replicação do vírus da imunodeficiência humana
JPWO2009131173A1 (ja)	2008-04-23	2011-08-18	協和発酵キリン株式会社	２−アミノキナゾリン誘導体
MX315904B (es)	2008-05-30	2013-11-29	Amgen Inc	Inhibidores de fosfoinosituro-3 cinasa.
GB0812969D0 (en)	2008-07-15	2008-08-20	Sentinel Oncology Ltd	Pharmaceutical compounds
KR20110050516A (ko)	2008-08-15	2011-05-13	바스프 에스이	나노 크기 유기 고체 입자 제조 방법
TW201639852A (zh)	2008-12-09	2016-11-16	吉李德科學股份有限公司	用於製備可用作類鐸受體調節劑之化合物的中間體化合物
US8389530B2 (en)	2008-12-29	2013-03-05	Fovea Pharmaceuticals	Substituted quinazoline compounds
CA2757679A1 (en)	2009-04-07	2010-10-14	Infinity Pharmaceuticals, Inc.	Inhibitors of fatty acid amide hydrolase
US8338441B2 (en)	2009-05-15	2012-12-25	Gilead Sciences, Inc.	Inhibitors of human immunodeficiency virus replication
WO2011035416A1 (en)	2009-09-25	2011-03-31	Aegera Therapeutics Inc.	Hsp90 modulating compounds, compositions, methods and uses
US20130165489A1 (en)	2010-05-03	2013-06-27	The Trustees Of The University Of Pennsylvania	Small Molecule Modulators of HIV-1 Capsid Stability and Methods Thereof
TW201210597A (en)	2010-06-09	2012-03-16	Gilead Sciences Inc	Inhibitors of hepatitis C virus
AR081960A1 (es)	2010-06-22	2012-10-31	Fovea Pharmaceuticals Sa	Compuestos heterociclicos, su preparacion y su aplicacion terapeutica
CA2803890A1 (en)	2010-06-25	2011-12-29	Rutgers, The State University Of New Jersey	Antimicrobial agents
MX2012015097A (es)	2010-07-02	2013-05-28	Gilead Sciences Inc	Derivados de acido naft-2-ilacetico para tratar sida.
US9296758B2 (en)	2010-07-02	2016-03-29	Gilead Sciences, Inc.	2-quinolinyl-acetic acid derivatives as HIV antiviral compounds
KR20130141500A (ko)	2010-09-29	2013-12-26	크리스탈지노믹스(주)	단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물
KR20120038060A (ko)	2010-10-13	2012-04-23	롬엔드하스전자재료코리아유한회사	신규한 유기 전자재료용 화합물 및 이를 포함하는 유기 전계 발광 소자
KR20130129244A (ko)	2010-12-17	2013-11-27	에프. 호프만-라 로슈 아게	치환된 6,6-융합된 질소 헤테로환형 화합물 및 이의 용도
WO2012116237A2 (en)	2011-02-23	2012-08-30	Intellikine, Llc	Heterocyclic compounds and uses thereof
EP3181555B1 (en)	2011-04-21	2018-11-28	Gilead Sciences, Inc.	Benzothiazole compounds and their pharmaceutical use
ES2553449T3 (es)	2011-07-06	2015-12-09	Gilead Sciences, Inc.	Compuestos para el tratamiento de VIH
CN102863512B (zh)	2011-07-07	2016-04-20	上海泓博智源医药技术有限公司	抗病毒化合物
JP6144698B2 (ja)	2011-12-20	2017-06-07	ベーリンガーインゲルハイムインターナショナルゲゼルシャフトミットベシュレンクテルハフツング	Ｈｉｖ複製の阻害剤としての縮合三環式化合物
MD20140063A2 (ro)	2012-04-20	2014-12-31	Gilead Sciences, Inc.	Derivaţi de acid benzotiazol-6-il acetic şi utilizarea acestora pentru tratarea unei infecţii HIV
AP2015008510A0 (en)	2012-12-21	2015-06-30	Gilead Sciences Inc	Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
PE20151063A1 (es)	2012-12-27	2015-08-03	Japan Tobacco Inc	DERIVADO SUSTITUIDO DE ESPIROPIRIDO[1,2-a]PIRAZINA Y USO MEDICO DEL MISMO COMO INHIBIDOR DE LA INTEGRASA DEL VIH
EP2769723A1 (en)	2013-02-22	2014-08-27	Ruprecht-Karls-Universität Heidelberg	Compounds for use in inhibiting HIV capsid assembly
EP2769722A1 (en)	2013-02-22	2014-08-27	Ruprecht-Karls-Universität Heidelberg	Compounds for use in inhibiting HIV capsid assembly
US9914709B2 (en)	2013-06-21	2018-03-13	Yale University	Compositions and methods of treating HIV-1 infections using same
TW202237569A (zh) *	2014-12-24	2022-10-01	美商基利科學股份有限公司	喹唑啉化合物
AU2015371257B2 (en)	2014-12-24	2018-09-06	Gilead Sciences, Inc.	Isoquinoline compounds for the treatment of HIV
MX2017008520A (es)	2014-12-24	2018-03-01	Gilead Sciences Inc	Compuestos de pirimidina fusionada para el tratamiento del virus de inmunodeficiencia humana (vih).

2015
- 2015-12-18 TW TW111121406A patent/TW202237569A/zh unknown
- 2015-12-18 TW TW109122699A patent/TWI770552B/zh active
- 2015-12-18 TW TW104142712A patent/TWI699355B/zh active
- 2015-12-22 AR ARP150104262A patent/AR103252A1/es unknown
- 2015-12-23 ES ES18213309T patent/ES2900810T3/es active Active
- 2015-12-23 CN CN202010295176.XA patent/CN111574464A/zh active Pending
- 2015-12-23 CN CN201580076616.XA patent/CN107278201B/zh active Active
- 2015-12-23 ES ES21187414T patent/ES2964395T3/es active Active
- 2015-12-23 PL PL15832711T patent/PL3237398T3/pl unknown
- 2015-12-23 SI SI201531719T patent/SI3521282T1/sl unknown
- 2015-12-23 KR KR1020177020449A patent/KR102049476B1/ko active Active
- 2015-12-23 CU CUP2017000089A patent/CU20170089A7/es unknown
- 2015-12-23 BR BR102015032361-1A patent/BR102015032361B1/pt active IP Right Grant
- 2015-12-23 DK DK18213309.0T patent/DK3521282T3/da active
- 2015-12-23 HR HRP20211543TT patent/HRP20211543T1/hr unknown
- 2015-12-23 UA UAA201707115A patent/UA117796C2/uk unknown
- 2015-12-23 MA MA048448A patent/MA48448A/fr unknown
- 2015-12-23 EP EP18213309.0A patent/EP3521282B1/en active Active
- 2015-12-23 PL PL18213309T patent/PL3521282T3/pl unknown
- 2015-12-23 CA CA2972021A patent/CA2972021C/en active Active
- 2015-12-23 MX MX2017008521A patent/MX367574B/es active IP Right Grant
- 2015-12-23 PT PT182133090T patent/PT3521282T/pt unknown
- 2015-12-23 MD MDA20170070A patent/MD4650B1/ro not_active IP Right Cessation
- 2015-12-23 HK HK18103444.6A patent/HK1244001B/zh unknown
- 2015-12-23 ES ES15832711T patent/ES2715507T3/es active Active
- 2015-12-23 HU HUE18213309A patent/HUE058296T2/hu unknown
- 2015-12-23 TR TR2019/03672T patent/TR201903672T4/tr unknown
- 2015-12-23 JP JP2017534259A patent/JP6367489B2/ja active Active
- 2015-12-23 PT PT15832711T patent/PT3237398T/pt unknown
- 2015-12-23 EA EA202091115A patent/EA202091115A1/ru unknown
- 2015-12-23 EP EP21187414.4A patent/EP3960735B1/en active Active
- 2015-12-23 EA EA201791256A patent/EA035746B1/ru unknown
- 2015-12-23 SI SI201530560T patent/SI3237398T1/sl unknown
- 2015-12-23 US US14/998,042 patent/US9730936B2/en active Active
- 2015-12-23 MY MYPI2017702362A patent/MY189761A/en unknown
- 2015-12-23 NZ NZ733174A patent/NZ733174A/en unknown
- 2015-12-23 PL PL21187414.4T patent/PL3960735T3/pl unknown
- 2015-12-23 KR KR1020197034431A patent/KR102288855B1/ko active Active
- 2015-12-23 PE PE2017001139A patent/PE20171306A1/es unknown
- 2015-12-23 WO PCT/US2015/000460 patent/WO2016105564A1/en not_active Ceased
- 2015-12-23 SG SG10202101143VA patent/SG10202101143VA/en unknown
- 2015-12-23 EP EP23196262.2A patent/EP4302830A3/en active Pending
- 2015-12-23 EP EP15832711.4A patent/EP3237398B1/en active Active
- 2015-12-23 AU AU2015371198A patent/AU2015371198B2/en active Active
- 2015-12-23 SG SG11201705215PA patent/SG11201705215PA/en unknown
- 2015-12-23 LT LTEP18213309.0T patent/LT3521282T/lt unknown
- 2015-12-23 CR CR20170281A patent/CR20170281A/es unknown
2017
- 2017-06-21 IL IL25305917A patent/IL253059B/en active IP Right Grant
- 2017-06-22 CL CL2017001675A patent/CL2017001675A1/es unknown
- 2017-06-22 EC ECIEPI201739611A patent/ECSP17039611A/es unknown
- 2017-06-22 DO DO2017000151A patent/DOP2017000151A/es unknown
- 2017-06-22 SV SV2017005471A patent/SV2017005471A/es unknown
- 2017-06-22 CO CONC2017/0006214A patent/CO2017006214A2/es unknown
- 2017-06-23 PH PH12017501191A patent/PH12017501191B1/en unknown
- 2017-06-23 MX MX2019009932A patent/MX2019009932A/es unknown
- 2017-06-24 SA SA517381826A patent/SA517381826B1/ar unknown
- 2017-06-27 US US15/634,527 patent/US10206926B2/en active Active
2018
- 2018-07-04 JP JP2018127603A patent/JP2018168181A/ja active Pending
2019
- 2019-01-04 US US16/239,578 patent/US10548898B2/en active Active
- 2019-09-25 IL IL269635A patent/IL269635B/en active IP Right Grant
- 2019-12-18 US US16/718,311 patent/US11304948B2/en active Active
2021
- 2021-11-10 CY CY20211100979T patent/CY1124726T1/el unknown
2022
- 2022-03-09 US US17/690,351 patent/US20230043136A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20170354656A1 (en)	2017-12-14
MD20170070A2 (ro)	2017-12-31
SI3237398T1 (sl)	2019-04-30
SG10202101143VA (en)	2021-03-30
JP2018500358A (ja)	2018-01-11
MY189761A (en)	2022-03-03
KR102288855B1 (ko)	2021-08-11
DOP2017000151A (es)	2017-09-15
PE20171306A1 (es)	2017-09-05
UA117796C2 (uk)	2018-09-25
SI3521282T1 (sl)	2021-11-30
US11304948B2 (en)	2022-04-19
EP3521282A1 (en)	2019-08-07
IL253059A0 (en)	2017-08-31
HRP20211543T1 (hr)	2022-01-07
EP3960735A1 (en)	2022-03-02
EP3960735B1 (en)	2023-09-13
EA201791256A1 (ru)	2018-04-30
IL269635A (en)	2019-11-28
EP4302830A3 (en)	2024-03-13
CR20170281A (es)	2017-11-08
KR20170131351A (ko)	2017-11-29
CN107278201B (zh)	2020-05-19
MX367574B (es)	2019-08-27
ES2900810T3 (es)	2022-03-18
EP4302830A2 (en)	2024-01-10
WO2016105564A1 (en)	2016-06-30
CO2017006214A2 (es)	2017-10-20
US10206926B2 (en)	2019-02-19
US20200360383A1 (en)	2020-11-19
EP3237398A1 (en)	2017-11-01
US9730936B2 (en)	2017-08-15
CN111574464A (zh)	2020-08-25
JP6367489B2 (ja)	2018-08-01
TR201903672T4 (tr)	2019-04-22
SG11201705215PA (en)	2017-07-28
US20230043136A1 (en)	2023-02-09
CN107278201A (zh)	2017-10-20
HUE058296T2 (hu)	2022-07-28
EP3960735C0 (en)	2023-09-13
AU2015371198A1 (en)	2017-07-13
CL2017001675A1 (es)	2018-05-11
EA202091115A1 (ru)	2021-01-29
IL253059B (en)	2019-10-31
TWI770552B (zh)	2022-07-11
JP2018168181A (ja)	2018-11-01
US20190134035A1 (en)	2019-05-09
CY1124726T1 (el)	2022-07-22
CA2972021C (en)	2020-04-28
EA035746B1 (ru)	2020-08-05
TW202237569A (zh)	2022-10-01
MX2017008521A (es)	2018-03-01
SV2017005471A (es)	2018-01-18
IL269635B (en)	2021-04-29
EP3521282B1 (en)	2021-08-25
MX2019009932A (es)	2019-10-02
MD4650B1 (ro)	2019-09-30
KR102049476B1 (ko)	2019-11-28
SA517381826B1 (ar)	2021-10-21
PH12017501191A1 (en)	2018-03-05
DK3521282T3 (da)	2021-09-27
BR102015032361B1 (pt)	2021-12-21
KR20190133068A (ko)	2019-11-29
US10548898B2 (en)	2020-02-04
WO2016105564A8 (en)	2016-10-06
EP3237398B1 (en)	2018-12-19
LT3521282T (lt)	2021-11-25
CA2972021A1 (en)	2016-06-30
PT3521282T (pt)	2021-11-29
TWI699355B (zh)	2020-07-21
PL3960735T3 (pl)	2024-03-18
NZ733174A (en)	2018-12-21
ES2964395T3 (es)	2024-04-05
ES2715507T3 (es)	2019-06-04
US20160250215A1 (en)	2016-09-01
AR103252A1 (es)	2017-04-26
CU20170089A7 (es)	2017-11-07
PL3521282T3 (pl)	2022-01-03
BR102015032361A8 (pt)	2021-08-31
PL3237398T3 (pl)	2019-05-31
PH12017501191B1 (en)	2021-08-06
ECSP17039611A (es)	2017-07-31
PT3237398T (pt)	2019-03-06
AU2015371198B2 (en)	2018-09-27
TW201636328A (zh)	2016-10-16
MA48448A (fr)	2021-04-28
BR102015032361A2 (pt)	2016-07-05
TW202106667A (zh)	2021-02-16

Publication	Publication Date	Title
EP3237398B1 (en)	2018-12-19	Quinazoline derivatives used to treat hiv
EP3237414B1 (en)	2019-05-08	Fused pyrimidine compounds for the tratment of hiv
EP3237397B1 (en)	2018-11-21	Isoquinoline compounds for the treatment of hiv
HK1244001A1 (zh)	2018-07-27	用於治療hiv的喹唑啉衍生物
HK1244270A1 (zh)	2018-08-03	用於hiv治療的融合嘧啶化合物
HK1244271A1 (zh)	2018-08-03	用於hiv治療的異喹啉化合物
HK40069165A (zh)	2022-10-07	用於治療hiv的喹唑啉衍生物
HK40011507B (zh)	2022-04-22	用於治療hiv的喹唑啉衍生物
HK40011507A (zh)	2020-07-17	用於治療hiv的喹唑啉衍生物